Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease

Isner, Jeffrey M.; Walsh, Kenneth; Symes, James F.; Pieczek, Ann; Takeshita, Satoshi; Lowry, Jason A.; Rossow, Susan; Rosenfield, Kenneth; Weir, Lawrence; Schainfeld, Robert M.

doi:10.1161/01.cir.91.11.2687

Cited by 235 publications

(123 citation statements)

References 34 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…In the clinical setting, the VEGF induced as a potent angiogenesis factor may not be sufficient to stimulate coronary collateral formation, therefore, administration of recombinant VEGF or VEGF genes to promote angiogenesis will be useful as a treatment for arteriosclerosis obliterans (ASO) and myocardial infarction in animal models and clinical patients. 5,33,34 On the other hand, the present data demonstrated that endogenously expressed HGF was markedly decreased in infarcted myocardium in the late phase (14 days), although the up-regulation of c-met has been previously reported in a myocardial infarction model in the acute phase. 35 Therefore, a sufficient supply of HGF by in vivo transfer of HGF gene into the infarcted myocardium would also enhance collateral formation.…”

Section: Figure 3 Effect Of the Transfection Of Hgf Vector On The Vascontrasting

confidence: 47%

Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets

et al. 2000

View full text Add to dashboard Cite

The feasibility of a novel therapeutic strategy using angiogenic growth factors to expedite and/or augment collateral artery development has recently entered the realm of treatment of ischemic diseases. Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors whose mitogenic activity on endothelial cells is very potent. Although it has been demonstrated that HGF is a potential angiogenic growth factor in in vitro culture systems, there is no direct in vivo evidence for the angiogenic activity of HGF in physiological conditions. In this study, we hypothesized that transfection of HGF gene into infarcted myocardium could induce angiogenesis, potentially resulting in a beneficial response to hypoxia. Human HGF gene or control vector driven by the SR␣ promoter was transfected into rat myocardium by the HVJ-liposome method. Four days after in vivo transfection of human HGF gene, there was a marked increase in human immunoreactive HGF as compared with control vector (P Ͻ 0.01). In myocardium transfected with HGF vector, a significant increase in PCNA-positive endothelial cells was observed, while few PCNA-positive endothelial cells were detected in both control-vector-transfected and untreated myocardium. The number of vessels around

show abstract

Section: Figure 3 Effect Of the Transfection Of Hgf Vector On The Vascontrasting

confidence: 47%

Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Indeed, the clinical utility of gene therapy using VEGF gene has been recently reported for the treatment of critical limb ischemia and myocardial ischemia. [4][5][6] The present study raises the possibility of a new strategy, therapeutic angiogenesis using HGF as gene therapy, instead of VEGF, for the treatment of patients with critical limb ischemia. HGF is a mesenchyme-derived pleiotropic factor which regulates cell growth, cell motility, and morphogenesis of various types of cells, and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis.…”

Section: Discussionmentioning

confidence: 89%

“…Recently, the efficacy of therapeutic angiogenesis using VEGF (vascular endothelial growth factor) gene transfer has been reported in human patients with critical limb ischemia and myocardial ischemia. [4][5][6] Thus, the strategy for therapeutic angiogenesis using angiogenic growth factors should be considered for the treatment of patients with critical limb ischemia or myocardial infarction. Most of the studies have used VEGF, also known as vascular permeability factor, as well as a secreted endothelial-cell mitogen.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease

et al. 2001

View full text Add to dashboard Cite

Hepatocyte growth factor (HGF) exclusively stimulates the growth of endothelial cells without replication of vascular smooth muscle cells, and acts as a survival factor against endothelial cell death. Recently, a novel therapeutic strategy for ischemic diseases using angiogenic growth factors to expedite and/or augment collateral artery development has been proposed. We have previously reported that intraarterial administration of recombinant HGF induced angiogenesis in a rabbit hindlimb ischemia model. In this study, we examined the feasibility of gene therapy using HGF to treat peripheral arterial disease rather than recombinant therapy, due to its disadvantages. Initially, we examined the transfection of 'naked' human HGF plasmid into a rat hindlimb ischemia model. Intramuscular injection of human HGF plasmid resulted in a significant increase in blood flow as assessed by laser Doppler imaging, accompanied by the detection of human HGF protein. A significant increase in capillary density was found in rats transfected with human HGF as compared with control vector, in a dose-dependent manner (P Ͻ 0.01). Importantly, at 5 weeks after transfection, the degree of angiogenesis induced by transfection of HGF plasmid was significantly greater than that caused by

show abstract

“…The application of hydrogel to human gene therapy has been reported by Isner and others. [19][20][21] They demonstrated that endoluminal vascular gene transfer can be achieved successfully and consistently with pure DNA applied to a standard angioplasty catheter balloon coated with hydrogel polymer. Indeed, the present data demonstrated relatively wide distribution of E2F decoy into balloon-injured porcine coronary arteries.…”

Section: Discussionmentioning

confidence: 99%

Molecular strategy using cis-element ‘decoy’ of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model

et al. 2002

View full text Add to dashboard Cite

show abstract

Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease

Cited by 235 publications

References 34 publications

Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets

Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease

Molecular strategy using cis-element ‘decoy’ of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model

Contact Info

Product

Resources

About